Verition Fund Management’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-18,201
Closed -$543K – 2419
2026
Q2
$543K Sell
18,201
-933
-5% -$24.5K ﹤0.01% 1614
2026
Q1
$571K Sell
19,134
-3,378
-15% -$149K ﹤0.01% 1540
2025
Q4
$933K Buy
+22,512
New +$774K ﹤0.01% 2203

Other funds holding MAZE

Verition Fund Management's MAZE Position: Q3 2026 in Review

Verition Fund Management sold out of Maze Therapeutics (MAZE) in Q3 2026, closing a stake of 18,201 shares — an estimated $543K sold.

Verition Fund Management first reported a position in MAZE in Q4 2025 and held it in 3 quarters. The position peaked at $933K in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Verition Fund Management reported no remaining Maze Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 18,201 Maze Therapeutics shares in Q3 2026, an estimated $543K.
  • Verition Fund Management first reported a position in Maze Therapeutics in Q4 2025 and held it in 3 quarters.
  • Verition Fund Management's Maze Therapeutics position peaked at $933K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.